SecBot SecBot
8-K ·Filed Nov 3, 2026

AEON

AEON Biopharma, Inc.
NEUTRAL
Impact 4/10
Horizondays Processed13d 15h ago SEC0001837607-26-000081
8-K Item 1.01 + 5.02 (likely routine officer/director compensation agreement)
Actionable Insight • Neutral

The $6.2M cash infusion is material for a $17M market cap company, but the reduced exercise price increases potential dilution. Monitor the actual number of shares issued upon exercise and the company's cash runway update.

DirectionNeutral
Confidencehigh
Horizondays

ABP-450

▼ Bearish Named in this 8-K
Impact
Phase
Pre-approval biosimilar (351(k)) development — analytical comparability stage; no active Phase 2/3 trial in local data a
Time to market
Unknown — several years at best. The program is still in FDA pathway-alignment (Type 2a meeting held Jan 2026; Type 2b planned 2H26); a BLA has not been filed and five-year milestone warrants are tied to Phase 3 trial initiation, so US approval is likely late-2020s or later if the biosimilar path succeeds.
Next catalyst
None dated

What to watchTreat the ~$6.70 two-analyst price target as a stale artifact set before the July 2026 re-IPO dilution (stock trades ~$0.26, near its 52-week low of $0.222). Watch the FDA Type 2b meeting in 2H26, its minutes trigger expiry of the two-year milestone warrants and could unlock up to $34M in additional gross proceeds, a potential double-edged catalyst: capital in, but at heavy dilution. Also monitor NYSE American compliance status after the August 3, 2026 deadline to regain listing standards.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$0.2122
T+0 close · Nov 3, 2026 · via day close
Latest settled
−15.50%
T+5 · $0.1793 · next T+20 in 15d
Vs SPY
−14.92%
α at T+5
Latest observation
−27.00%
T+8 · FF3 residual α
  1. T+0 · Nov 3 $0.2122entry
  2. T+1 · 13d ago −1.70%α −3.35% · $0.2086
  3. T+5 · 7d ago −15.50%α −14.92% · $0.1793
  4. T+9 · todayOpen
  5. T+20 · in 15d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AEON Biopharma amended its outstanding two-year milestone warrants, reducing the exercise price from $0.3221 to $0.20 per share of common stock. In exchange, certain holders agreed to exercise their warrants, and the company expects to receive approximately $6.2 million in gross proceeds. The warrants expire on November 16, 2026.

Key Financial Metrics

Deal Value
$6.2M

Key Facts

  • Warrant exercise price reduced from $0.3221 to $0.20 per share of common stock
  • Company expects approximately $6.2 million in gross proceeds from warrant exercises
  • Warrants expire on November 16, 2026
  • 71,517,020 shares of common stock outstanding as of October 30, 2026
  • Amendment applies to all outstanding two-year warrants, not just those of consenting holders

Financial Impact

Approximately $6.2 million in gross proceeds from warrant exercises, representing about 36% of the company's $17 million market cap

cashdilution

Risk Factors

  • Dilution from warrant exercises could pressure the stock price
  • Warrants expire on November 16, 2026, creating a near-term catalyst for share issuance
  • Company has no stated revenue or earnings in the filing, making fundamental valuation difficult

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001837607-26-000081
Document: aeon-ex4d2.htm0001837607-26-000081
Document: 0001837607-26-000081-index-headers.html0001837607-26-000081
Document: 0001837607-26-000081.txt0001837607-26-000081

Track record

22 reports on AEON

Performance horizon

8 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +44.50% at T+60 after the Jul 9, 2026 report. 9 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $0.1600 Now $0.1410 −11.87% settles Nov 24
  2. Nov 16, 2026today Press Release Neutral 5/10 Entry $0.1410 Now $0.1410 +0.00% settles Nov 24
  3. Nov 13, 20263d ago SC 13G Neutral 4/10 Entry $0.1610 Now $0.1410 −12.42% settles Nov 23
  4. Nov 10, 20266d ago SC 13D/A Neutral 3/10 Entry $0.1793 Now $0.1410 −21.36% settles Nov 17
  5. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $0.1818 to $0.1407 Now $0.1410 −22.44% ▼ −22.61% −20.91% vs SPY
  6. Nov 3, 202613d ago 8-K Neutral 4/10 Viewing Entry $0.2122 to $0.1793 Now $0.1410 −33.55% ▼ −15.50% −14.92% vs SPY
  7. Oct 26, 202621d ago DEF 14A Neutral 3/10 Entry $0.2483 to $0.2122 Now $0.1410 −43.21% ▼ −14.54% −12.55% vs SPY
  8. Oct 23, 202624d ago 8-K Neutral 4/10 Entry $0.2400 to $0.2740 Now $0.1410 −41.25% ▲ +14.17% +15.43% vs SPY
  9. Sep 30, 20266w ago 8-K Bullish 7/10 Entry $0.3000 to $0.3110 Now $0.1410 −53.00% ▲ +3.67% +1.75% vs SPY
  10. Aug 21, 202612w ago 3 Neutral Not scored Entry $0.1974 to $0.2959 Now $0.1410 −28.57% ▲ +49.90% +49.43% vs SPY
Showing 10 of 22

US Market Status

Market Closed · Opens in 9h 18m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026